Can J Psychiatry 2008;53 (7): [430][431][432] I t is widely accepted that the most powerful research design to assess the efficacy and effectiveness of a novel intervention is the RCT, in which one group of eligible patients is randomly assigned to receive the new drug and the other group receives something else. The question is, What should constitute that comparator condition? In situations where there is no effective treatment or where the existing treatment has many undesirable side effects, the answer is relatively straightforward: the comparison group should be a placebo. A much more difficult situation arises when an effective treatment does exist, such as selective serotonin reuptake inhibitors for depression or the atypical antipsychotics for schizophrenia. More than a decade ago, Rothman and Michels 1 argued very cogently that under such circumstances, it is a violation of the Declaration of Helsinki to have a placebo arm in the trial, as that would deny patients available treatment, and that the comparison should be against TAU. However, the sheer number of letters to the editor in response to that article is an indication that the issue is neither clear-cut nor settled.
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At first glance, Rothman and Michels' points are very compelling. If a drug already exists, how can we refuse to give it to some patients? From a scientific point of view, why would we even consider using a placebo? Aside from the pecuniary reason of pharmaceutical companies wanting to introduce their "me too" version of a drug, it would seem reasonable that the correct scientific question should not be, Does this new drug also work for this condition? but rather, Does this new drug work better or have fewer ADRs than the existing treatment(s)? My position is that this argument would be unassailable if this were le meilleur des mondes possibles. However, despite Dr Pangloss' unwavering belief, this is not the best of all possible worlds. In light of that, placebo-controlled trials are a necessary evil, even when effective drugs exist. My arguments are 2-fold: first, the results of studies with 2 active drugs may be ambiguous and impossible to interpret; and second, more people are potentially left untreated or harmed in trials with active controls, compared with placebo controls.
Regarding the first point, there are 2 possible outcomes in any clinical trial: the study finds a statistically significant (and ideally, clinically important) difference between the drugs in one direction or the other, or it does not. If the first situation is obtained, then there is no ambiguity: the new drug was either superior or inferior in comparison to TAU, and should or should not be adopted. The problem arises when the study finds no significant difference. This can occur for 1 of 2 reasons: both drugs were equally effective, or in this trial, both drugs were equally ineffective. However, if TAU has been shown to work in earlier studies, how can it occur that it was ineffective in the current trial? This is not merely a theoretical question. One metaanalysis found that, among 52 trials, only 48% of antidepressant arms showed superiority over a placebo; and the same proportion was seen in 13 trials of anxiolytics. 2 Let us go through the steps of executing an RCT with a new drug. First, patients are assessed to determine whether they meet the inclusion criteria. Second, those who satisfy the criteria are randomly assigned to one of the 2 groups. Third, therapeutic dosages of both drugs are given in a doubleblinded manner to all patients for a time sufficient for them to show an effect. Fourth, relevant outcomes are measured in an unbiased and blinded manner for all patients who entered the trial. Finally, the data are accurately and competently analyzed to see if the new drug is superior, or equivalent in effect but has fewer ADRs. The problem is that any given study can fall short of the ideal at one or more steps, resulting in a type II error (that is, failing to detect an effect when it is present) for the proven drug, and therefore a lack of difference in comparison to an ineffective new one.
Regarding selection of appropriate patients, we found that a major factor influencing the ES in trials of tricyclic antidepressants was the manner in which patients were diagnosed 3 : studies with large ESs had used formal diagnostic criteria, whereas those with small ESs had used clinical judgment. Our conclusion was that the ESs were smaller because these studies included a larger proportion of patients who did not meet DSM criteria for depression.
Although most clinical trials claim that patients are randomly assigned (step 2), the adequacy of that process has been questioned in many cases. One review of 183 self-declared RCTs in psychiatry concluded that "The RCT status of some of the papers must therefore be in doubt." 4, p 581 This is important because there is some evidence that inadequate concealment of the randomization process can result in biased estimates of effectiveness. 5 The third stage, a therapeutic dosage given in a doubleblinded manner, can be jeopardized in 2 ways: inappropriate dosage and lack of blinding. Heres et al 6 found that, in head-to-head comparisons of antipsychotics, results favoured the drug of the trial's sponsor, owing, in part, to inappropriate dosages of the comparator drug. The loss of blinding was illustrated by Margraf et al, 7 who found that most patients with panic disorder and their physicians were able to determine whether they received the active drug or a placebo, throwing into question the double-blinded nature of the study. While this is less of an issue when 2 active treatments are compared, new drugs are often introduced because they purportedly have a better side-effect profile, so that the issue does not disappear in such circumstances.
The fourth stage of a trial, completeness of follow-up, is where studies are most vulnerable. A recent metaanalysis of 31 trials of antipsychotic agents 8 found drop-out rates between 28% and 55%, leading to serious questions about both the internal and the external validity of these trials. Data analysis and presentation are the final stage. Chan et al 9 compared 122 research protocols encompassing 3736 unique outcomes with the papers that were later published. They found that 50% of efficacy and 65% of harm outcomes per trial were incompletely reported; in 62% of the cases, the primary outcome was changed, introduced, or omitted; and significant findings were more than twice as likely to be reported as nonsignificant ones.
As a final note regarding design, noninferiority trials are not a panacea. To a greater degree than for superiority studies, the results are influenced by design considerations. The best way to prove equivalence is to design and execute a truly terrible study, with inadequate sample size, low completion rates, inappropriate measures, and intention-to-treat analyses. 10 Further, the more similar the drugs must be to be deemed equivalent, the larger the required sample size-most often much larger than for superiority trials. 11 Thus, a trial showing no difference between 2 drugs, even if one has previously been shown to be effective, can be the result of equivalent effectiveness or study deficiencies. This ambiguity cannot be resolved unless there is a placebo group, against which both agents can be assessed. If both active drugs are superior to placebo, then both are effective; if neither is superior, then the trial was deficient in some way and we are dealing with a type II error.
The second argument in favour of placebo controls is that, paradoxically, fewer people are at risk of ADRs. Assume that the placebo response is 30%, which is commonly found in studies in depression, and we are testing whether a new drug will help 50% of patients. Under such circumstances, about 100 patients are needed in each group. If the comparison group were another drug, with 40% effectiveness, then the required sample size is 400 in each arm. If the probability of harm were the same for both drugs, then 100 are at risk in a placebo-controlled trial (those in the treatment arm), but 800 are at risk in an active-controlled study (those in both conditions). By the same token, while 60% of patients in the placebo-controlled study would not show any improvement (70% in the placebo group and 50% taking the new drug), the number is not much less in the active-control study: 60% with the old drug, and 50% with the new, for an overall nonimprovement rate of 55%.
These numbers assume that the new treatment will eventually come onto the market because it is effective. However, this is not the case. Let us assume that only 50% of drugs are eventually approved. That means that the number of people receiving an ineffective drug in the placebo-controlled condition is 100 (the placebo arm) plus 50 (that is, there is a 50% chance that those receiving the new treatment will not get an effective drug). In an active-controlled situation, the number will be 200 (none in the comparison arm plus 50% of the 400 receiving the new treatment). In fact, only if more than two-thirds of all new drugs are proven effective will there be fewer ineffectively treated people in an active-controlled trial than a placebo-controlled one.
Thus, placebo-controlled studies are justified because the results are unambiguous, fewer people are exposed to ADRs, and the number of people receiving ineffective treatment is likely lower.
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